INSIGHTS ON DRUG DEVELOPMENT

• Lightning-Link^® Conjugation Kits: Consistent Performance On A Broad Scale

  Learn about labeling technology offering a transformative solution through direct antibody labeling without the need for post-conjugation purification, thereby mitigating antibody loss and ensuring reproducible results.

• A Study To Assess Organoid Size And Cell Count From 3D Image Analysis

  Recent advancements in 3D patient-derived organoids (PDOs) offer improved predictive power over traditional 2D assays. Explore a patented bioprocess for PDO expansion that could revolutionize drug discovery, especially in oncology.

• A Comparison To Traditional Clone Screening Platforms

  See how 46 CHO clones performed across automated, deep-well, and microbioreactor fed-batch cultures, using cell density, viability, and IgG concentration to evaluate clone performance.

• How Lipid Nanoparticles Enable Next-Gen Delivery

  Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.

• Accelerating Small Molecule Protein Degrader Development Using High-Content Imaging

  5/6/2026

  High‑content imaging enables rapid discovery and optimization of small‑molecule protein degraders by delivering multiparametric, single‑cell insights that accelerate hit identification, SAR development, and lead advancement.

• Producing Quality APIs At Scale

  5/7/2026

  Targeted process optimization transformed an early‑phase API with yield and impurity challenges into a scalable, high‑quality manufacturing process ready to support ongoing drug development.

• Eliminate Risk From Your Viral Vector Tech Transfers

  12/5/2025

  Explore strategies to simplify viral vector tech transfers, reduce risk, and maintain quality under tight timelines, as well as a case study that demonstrates how to streamline this critical process.

• Developing Non-PEG Stabilizer Lipids For Nucleic Acid Lipid Nanoparticles

  7/1/2026

  Non-PEG stabilizer lipids may offer a new path for LNP design. Combining strong colloidal performance with greater chemical flexibility helps address growing concerns around PEG-related immunogenicity.

• Quicker Development Using Cell Line Integration, End-To-End Support

  6/19/2025

  Despite challenges with mammalian host cell line diversity, Lonza's mitigation strategies drive efficiency and reproducibility, maximizing cell growth and product quality.